Biomarker and Edema Attenuation in IntraCerebral Hemorrhage (BEACH) is a trial studying the safety and tolerability of MW01-6-189WH, a small-molecule drug called MW189, in patients with intracerebral hemorrhage (ICH). There is currently no approved treatment for ICH, a condition that results in high rates of mortality and long-term disability.
In animal studies, MW189 was shown to effectively reduce neuroinflammation and decrease cerebral edema, which led to improved functional and cognitive performance. The goal of BEACH is to see if MW189 produces similar effects in humans with intracerebral hemorrhage.
BEACH is a multicenter, prospective, randomized, phase 2a, double-blind, placebo-controlled trial. This study plans to enroll 120 participants across 10 sites within the United States. Johns Hopkins University is collaborating with the University of Kentucky on this National Institute on Aging-funded trial, and BIOS CTCC will serve as the clinical and data coordinating center for this study.
ClinicalTrials.gov Identifier: NCT05020535